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Abstract: Contrast-enhanced magnetic resonance imaging (CE-MRI) is an important clinical 
tool for diagnosing neurological diseases. The appropriate use of a suitable MRI contrast agent 
or contrast pharmaceutical is essential for CE-MRI to produce desirable diagnostic images. 
  Currently, there are seven contrast agents (CAs) or pharmaceuticals approved for clinical imaging 
of the central nervous system (CNS) in the US, Europe, or Japan. All of the clinically approved 
CAs are water-soluble gadolinium-based contrast agents (GBCAs) which do not penetrate the 
CNS blood–brain barrier (BBB). These agents are used for imaging CNS areas without a BBB, 
or various pathologies, such as tumors and infection that break down the BBB and allow CAs to 
enter into the surrounding parenchyma. Clinically, GBCAs are most useful for detecting primary 
and secondary cerebral neoplastic lesions. Among these CNS GBCAs, gadobutrol (Gd-BT-
DO3A, Gadovist™) is a neutral, nonionic, macrocyclic compound that showed promising 
results from clinical trials of CNS imaging. In comparison with other GBCAs, Gd-BT-DO3A 
has relatively high in vitro kinetic stability and r1 relaxivity. Gd-BT-DO3A has been recently 
approved by the US Food and Drug Administration (FDA) in 2011 for CNS imaging. A review 
of available literature shows that Gd-BT-DO3A exhibits similar safety and clinical efficacy 
profiles to other GBCAs. Gd-BT-DO3A has the distinguishing feature that it is the only clinical 
agent commercially available in a formulation of 1.0 M concentration with a relatively higher 
in vitro T1 shortening per unit volume than other clinical GBCAs which are only available in 
0.5 M concentration. This double concentration of Gd-BT-DO3A may allow a relatively higher 
concentration of the agent to localize in the CNS and produce a better contrast enhancement 
at the same clinical dose as other GBCAs. Several recent published multicenter clinical trials 
appeared to support this potential advantage of Gd-BT-DO3A.
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Introduction
Current clinical magnetic resonance imaging (MRI) produces images by measuring the 
radiofrequency (RF) signals that arise from exposing water protons (1H) in living tissues of 
the patient to a high external magnetic field created by the clinical MRI imagers.1,2 Because 
the magnetic properties of 1H are sensitive to the local microstructure and tissue composi-
tion, detailed anatomical images of high resolution as well as physiological information 
such as tissue perfusion and blood flow can be quantified by specific MRI measurement. 
The normal contrast in the clinical MRI images represents the relative difference in signal 
intensities between two adjacent regions displayed on a gray (or color) scale. The major 
contributing factors to the signal intensities are the proton longitudinal relaxation time 
(T1) and transverse relaxation time (T2). However, there are many pathological conditions 
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that do not lead to sufficient MRI signal intensity difference 
between normal and abnormal tissues because of the intrinsic 
insensitivity of MRI. In these conditions, the pathology may be 
detected by introducing exogenous MRI contrast agents (CAs) 
or contrast pharmaceuticals to locally change the magnetic 
properties of the diseased tissue. Frequently, the sensitivity 
and accuracy of clinical MRI in diagnosis of diseases are sig-
nificantly increased by the utilization of CAs that have been 
proven to be safe for human use.
MRI plays an important role in the detection,   diagnosis, 
and management of patients with various neurological 
diseases.3–5 With recent advances in technologies, MRI offers 
high physiological sensitivity and spatial resolution of the 
brain.6,7 Some of these capabilities arise from the use of exoge-
nous contrast pharmaceuticals to enhance the contrast between 
normal and abnormal tissues of the central nervous system 
(CNS). This contrast-enhanced MRI (CE-MRI) approach 
improves sensitivity, increasing the detection and delinea-
tion of normal and pathological structures in CNS clinical 
studies. Current clinical CE-MRI of the CNS mainly utilizes 
CAs that consist of the paramagnetic gadolinium(III) (Gd3+) 
chelated to various non-toxic molecules to reduce the inher-
ent free Gd3+ ion biological toxicity.6,8–10 Gd3+, a lanthanide 
metal ion with seven unpaired electrons, has been shown to 
be very effective at enhancing proton relaxation because of its 
high magnetic moment and very labile water coordination.2,6–9 
These water-soluble paramagnetic contrast agents are gener-
ally metal chelates that work as positive CAs by shortening the 
T1, T2, and T2* relaxation time constants of surrounding water 
protons to indirectly produce the signal-enhancing effect.8 At 
normal clinical doses of 0.1–0.2 mmol/kg, the T1 effect tends 
to dominate. All of the gadolinium-based CAs (GBCAs) 
that are approved for clinical use in humans are nonspecific 
agents, and their clinical use in CNS imaging is limited by 
the blood–brain barrier (BBB). There are negative CAs such 
as superparamagnetic particles/nanoparticles which primarily 
shorten T2 and T2* but none of these agents are commercially 
available for clinical applications for CNS imaging. With a 
better understanding of the complex contrast enhancement 
mechanism as well as advances in the field of cellular and 
molecular imaging, specific tissue/molecular-targeted CAs 
that can penetrate the BBB and smart-activated/responsive 
CAs are under active investigations that may lead to more 
specific targeted imaging in the future.1,2,11–14
The GBCAs for CE-MRI of CNS are primarily focused 
on detecting CNS lesions.4,5 After intravenous (IV) injection, 
these low molecular weight gadolinium chelates distribute 
from the bloodstream into the intravascular, extravascular, 
and extracellular spaces of the body.3 These agents rapidly 
equilibrate between intravascular and extravascular spaces 
with up to 50% first pass extraction fractions. The CNS pres-
ents a different environment from the rest of the body because 
of the existence of the BBB.15,16 The BBB is a network of 
blood vessels formed by very closely spaced endothelial cells 
with tight junctions to prevent diffusion of large molecular 
weight substances into the brain parenchyma. As a result, 
the use of CAs in the CNS is a challenge but also provides 
considerably different diagnostic applications, analysis 
opportunities and physiological inferences.3,16 All current 
commercially available MRI contrast pharmaceuticals do not 
cross the intact BBB. An intact BBB prevents the extravasa-
tion of these agents from blood vessels into the surrounding 
brain parenchyma. They are retained intravascularly in the 
CNS regions with intact BBB. Thus, contrast enhancement 
with these agents only occurs in the CNS regions without 
the BBB in healthy adult brains. These regions include the 
choroid plexus, the pituitary gland and infundibulum, the 
cavernous sinus, and nasal mucosa. Other possible structures 
may include vessels, dura mater, and falx cerebri. However, 
a variety of pathological conditions such as tumors, infarc-
tions, infection, and acute demyelination may cause the BBB 
to break down and allow these MRI contrast agents to cross 
into the extracellular space of CNS lesions.
Table 1 shows some examples of the CE-MRI of selected 
CNS pathologies.15 In these cases of BBB breakdown, small or 
multiple CNS lesions are more clearly delineated with contrast 
enhancement. More importantly, contrast enhancement can 
highlight lesion vasculature, delineate the extent of disease, and 
confirm the impression of normal or nonmalignant tissues.1,2,5 
Thus, CE-MRI of the brain lesions can provide important ana-
tomical information about brain   pathology, detailed depiction of 
Table 1 Examples of CE-MRI used for selected CNS lesions5
CNS lesions Enhancement/clinical 
observations
Intraparenchymal  
tumors/metastases
Early detection of small metastases 
Useful for delineation and 
specificity of high grade gliomas
Meningeal tumors/meningioma Focal/nodular enhancement
Cerebellopontine angle and  
internal/auditory canal lesions
very strong enhancement
Inflammation/acute disseminated  
encephalomyelitis
In case of BBB breakdown
Infection In case of BBB breakdown, there  
is rim enhancement in abscesses
Ischemia and acute infarction Depending on stage
Abbreviations:  CE-MRI,  contrast-enhanced  magnetic  resonance  imaging; 
CNS, central nervous system; BBB, blood–brain barrier.
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lesion morphology, and the overall extent of disease. Combined 
with advanced functional MRI techniques such as dynamic 
contrast-enhanced perfusion-weighted imaging, CE-MRI also 
provides physiological information regarding the hemodynam-
ics and neoangiogenic status of the CNS lesion.11
Clinically, CE-MRI is most commonly used to evalu-
ate primary and secondary CNS tumors.3 CE-MRI of 
CNS tumors provides sensitive detection and an accurate 
description of the disease in terms of tumor grade and 
  aggressiveness.   CE-MRI is an invaluable tool for identify-
ing critical structures for neurosurgical or radiotherapeutic 
intervention. In addition, it is also very useful for determining 
and monitoring treatment response.
Gadolinium-based MRI contrast 
pharmaceuticals used in clinical  
CE-MRI
There are various GBCAs that are either available for clini-
cal use in humans or under development at various stages 
of investigation.1,6,11,17 They can be classified based on their 
molecular structures or physicochemical properties. For clini-
cal applications, these GBCAs are most commonly classified 
based on their in vivo tissue distribution: extracellular, intra-
cellular, tissue-specific, or blood pool/intravascular contrast 
agents (Table 2).1,3,6,11,17,18 There are nine GBCAs approved 
for intravenous administration for CE-MRI. Seven of these 
agents are approved for used in CE-MRI of the CNS. All of 
these agents are non-specific extracellular agents and lack 
specificity for typing cancers for the purpose of differential 
diagnosis.13,14
Gadopentetate dimeglumine (Gd-DTPA) was the first 
intravenous MRI contrast agent used clinically, and a number 
of similar Gd chelates have been developed in an effort to 
further improve clinical efficacy, patient safety, and patient 
tolerance.1,6 The major chemical differences among these 
GBCAs are the presence or absence of overall charge, ionic 
or nonionic, and their ligand frameworks (linear or macro-
cyclic) (Table 3).3,18,19
Some important properties of GBCAs are high 
solubility, high relaxivity, low toxicity, low osmolality, 
thermodynamic and kinetic stability, and number of water 
coordination sites.2,7,18,20,21 Chemically, hydrophilicity is 
important because high overall hydrophilicity is associated 
with very low protein binding and good biological tolerance. 
All GBCAs are nine-coordinate complexes in which a ligand 
occupies eight binding sites at the Gd3+ metal center, and 
the ninth coordination site is occupied by a water molecule. 
Kinetic stability is an important factor as related to the 
safety of GBCAs in causing nephrogenic systemic fibrosis 
(NSF).18,19,22,23 The kinetic stability is generally related to 
the potential dechelation reaction or transmetallation of 
the GBCAs that results in the release of the toxic free Gd3+ 
in vivo. Idee et al18 proposed three classes of GBCAs based 
on their experimentally determined in vitro results in the 
presence of Zn2+ at pH 7.4 (Table 2).19,22,23 The classes are 
as follows:
1.  macrocyclic chelates (Gd-DOTA, Gd-HP-DO3A, and 
Gd-BT-DO3A) with very high kinetic stability;
2.  ionic, open-chain chelates (Gd-DTPA, Gd-BOPTA) with 
moderate kinetic stability;
3.  nonionic, open-chain chelates (Gd-DTPA-BMA and 
Gd-DTPA-BMEA) with poor kinetic stability.
Both renal and extrarenal toxicities have been reported 
following the clinical use of GBCAs in patients with underly-
ing kidney disease.24–26 In 2007, the United States Food and 
Drug Administration requested that all manufacturers of 
GBCAs add new warnings about how exposure to GBCAs 
increases the risk for NSF in patients with advanced kidney 
disease. The stability of GBCAs appears to be an important 
factor in the pathogenesis of NSF.7 It is postulated that 
GBCAs of relatively low stability may release free Gd3+ 
ions that lead to the initiation of the fibrosis process. Idee 
et al18 suggested that high kinetic stability combined with a 
Table 2 Approved clinical intravenous GBCAs in the US, EU,   
and Japan
GBCA  
(trade name)
Approved  
indications
Approval  
status
Approved adult   
CNS dose  
(mmol/kg)
Gadopentate 
(Magnevist™)
CNS,  
whole body
US, EU,  
Japan
0.1–0.2
Gadodiamide 
(Omniscan™)
CNS,  
whole body
US, EU,  
Japan
0.1–0.3
Gadoterate  
(Dotarem™)
CNS,  
whole body
EU 0.1–0.3
Gadoteridol 
(Prohance™)
CNS,  
whole body
US, EU,  
Japan
01–0.3
Gadobutrol  
(Gadovist™)
CNS US, EU 0.1–0.3
Gadobenate  
(MultiHance™)
CNS, liver US, EU 0.1
Gadoversetamide  
(OptiMARK™)
CNS, liver US 0.1
Gadoxetic acid  
(Primovist™) – EU 
(Eovist™) – USA
Liver US, EU Not approved
Gadofosveset  
(vasovist™)
Abdominal and  
limb vessels
EU Not approved
Abbreviations: GBCA, gadolinium-based contrast agents; CNS, central nervous 
system.
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high thermodynamic stability can minimize the amount of 
free Gd3+ in vivo.
Development of gadobutrol
Based on the aforementioned physicochemical properties 
required for a clinically useful GBCA, Gd-BT-DO3A was 
developed for lower toxicity and higher dose   concentration. 
Gd-BT-DO3A has a macrocyclic framework and is 
neutral.21,27 The BT-DO3A ligand was developed based on 
the belief that high overall hydrophilicity of an agent is 
generally associated with very low protein binding and good 
biological tolerance.21 It is a modification of the Gd-DO3A 
compound in which a trihydroxybutyl group is attached to 
the macrocyclic ligand to ensure high hydrophilicity. The 
ligand contains two chiral carbons at C-13 and C-14, and 
therefore the product is a racemic mixture of (13R,14S)- and 
(13S,14R)-. The Gd(III) in Gd-BT-DO3A has a coordina-
tion number of 9. Gd-BT-DO3A is a water-soluble, highly 
hydrophilic compound with a partition coefficient between 
n-butanol and buffer at pH 7.6 of ∼0.006.28
Gd-BT-DO3A was first synthesized by Vogler et al29 
based on the general method for preparing the macrocyclic 
core using the Richman–Atkins method. Later, Platzek et al21 
described three approaches to synthesizing the BT-DO3A 
ligand. One approach was preferred because it involved 
fewer steps and allowed scaled-up production for clinical 
applications. In this approach, 1-(1-[hydroxymethyl]-2,3-
dihydroxypropyl)-1,4,7,10-tetraazacyclododecane tetra-
hydrochloride was first prepared. The compound was then 
reacted with chloroacetic acid at 70°C and pH 9–10 for 
18 hours. Gd-BT-DO3A was then prepared by adding Gd2O3 
to the ligand in water and stirring at 90°C for 6 hours. Cation 
and anion exchange resins were then added at room tempera-
ture, and the mixture was stirred for 30 minutes. The resins 
were recollected by filtration, and charcoal was added to 
the filtrate and refluxed for 1 hour. The solution was filtered 
and evaporated to dryness. The residue was re-dissolved in 
water and ethanol, and then was refluxed for 2 hours. Gd-BT-
DO3A was collected by filtration and drying under vacuum 
(12 hours at 60°C). The final yield was 87%.
In vitro and preclinical animal 
studies of Gd-BT -DO3A
Pintaske et al30 determined the in vitro relaxivity of Gd-BT-
DO3A and other compounds (Gd-DTPA and Gd-BOPTA) 
in human plasma obtained from healthy volunteers. 
M  easurements of Gd-BT-DO3A in concentrations of 
0.01 mM up to 64 mM at 37°C were made with 0.2-, 1.5-, and 
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3.0-Tesla (T) clinical scanners. The longitudinal relaxation 
rates (r1; liter × mmoL-1 × s-1) of Gd-BT-DO3A were 5.5 ± 0.3, 
4.7 ± 0.2, and 3.6 ± 0.2, at 0.2, 1.5, and 3 T, respectively. 
The transverse relaxation rates (r2; liter × mmoL-1 × s -1) 
were 10.1 ± 0.3, 6.8 ± 0.2, and 6.3 ± 0.3, at 0.2, 1.5, and 
3 T, respectively. In comparison, these values were lower for 
Gd-DTPA but higher for Gd-BOPTA.
Vogler et al29 measured the in vitro physicochemical prop-
erties of Gd-BT-DO3A. The osmolality was found to be 0.57 
osmol/kg for the 0.5 M concentration and 1.39 osmol/kg for 
the1 M concentration. The distribution coefficient (butanol/
water) was 0.006, and the viscosity was 1.43 cP for the 0.5 M 
concentration and 3.7 cP for the 1 M concentration. The 
T1-relaxivity (liter × mmoL-1 × s-1) in plasma was determined 
to be 5.6 at 0.45 T and 6.1 at 2 T. There was negligible protein 
binding of about 2.7% in plasma. With use of rat mast cells, 
the I50 (the concentration at which histamine was released) 
was found to be greater than 250 mM. The I50 value for 
lysozyme inhibition (the concentration at which 50% of the 
enzyme was inhibited) was greater than 300 mM.
Vogler et al29 studied the long-term elimination and 
biodistribution of 0.25 mmol/kg Gd-BT-DO3A in rats. More 
than 90% of the intraperitoneally injected dose (ID) was 
excreted by the kidneys in 2 hours and 100% in 7 days. The 
total amount remaining in the body decreased from 0.71% 
ID on day 1 to 0.15% ID on day 7 after injection. The acute 
toxicity (lethal dose [LD50]) in mice was 23 mmol/kg. In a 
neural tolerance study, the median LD50 (lethal dose; n = 10) 
and effective dose (ED50) of Gd-BT-DO3A in rats after 
intracisternal injection were 86 µmol/kg and 18 µmol/kg, 
respectively. In comparison, the LD50 and ED50 for Gd-DTPA 
were 740 µmol/kg and 73 µmol/kg, respectively. The study 
suggested that macrocyclic compounds had lower cerebral 
tolerance and that linear compounds had higher cerebral 
tolerance. Imaging studies in rat models with cerebral infarct, 
brain tumors, and intramuscular tumors showed contrast 
enhancements in all three pathologic areas. A dose-dependent 
increase in the signal intensity of the intramuscular tumors 
was observed. Several rat studies31–35 showed that Gd-BT-
DO3A was effective in providing contrast enhancement for 
MRI in glioma, brain ischemia, hepatocellular carcinoma, 
and the lymphatic system.
Attenberger et al36 compared lesion enhancement using 
1 M Gd-BT-DO3A concentration with 0.5 M concentra-
tion Gd-DTPA and Gd-DOTA in a rat brain glioma model 
at 3 T MRI. At doses of 0.1 mmol/kg of all three agents, 
the results of groups of 9–10 rats showed Gd-BT-DO3A 
produced significantly higher signal-to-noise ratio (SNR) 
and contrast-to-noise ratio (CNR) than those of Gd-DTPA 
and Gd-DOTA. The authors concluded that the superior T1 
relaxivity property of Gd-BT-DO3A translated into more 
effective brain tumor enhancement at 3 T MRI imaging than 
both Gd-DTPA and Gd-DOTA. In a similar study at 1.5 T 
MRI, the same group of investigators37 also found consis-
tently greater tumor enhancement produced by Gd-BE-DO3A 
than those of Gd-DTPA and Gd-DOTA. Kramer et al38 also 
found Gd-BT-DO3A (0.1 mmol/kg) produced significantly 
higher CNR and SNR than Gd-DOTA (0.15 mmol/kg) in a 
rat brain glioma model at 1.5 and 3 T MRI.
Vogler et al29 performed Gd-BT-DO3A pharmacokinetics 
studies in beagle dogs. The elimination t½ and the plasma clear-
ance were 45 ± 3.6 minutes and 3.75 ± 0.30 mL/minute/kg, 
respectively. The total volume of distribution at steady state 
(Vss) was 0.23 ± 0.02 L/kg. High-performance liquid chroma-
tography analysis of the plasma and urine samples showed 
that Gd-BT-DO3A was not metabolized.
Clinical studies of Gd-BT -DO3A
Staks et al39 investigated the pharmacokinetics, dose 
proportionality, and tolerability of Gd-BT-DO3A in healthy 
volunteers. Two double-blind, randomized, placebo-controlled 
Phase I studies were conducted for testing a low concentration 
(0.5 M; doses = 0.04, 0.1, 0.2, 0.3, and 0.4 mmol/kg; 
n = 55) and a high concentration (1 M; doses = 0.3, 0.4, 
and 0.5 mmol/kg; n = 36). From the data for 24 volunteers, 
pharmacokinetic parameters were calculated from an open 
two-compartment model. The values for plasma elimination 
half-life (t½p,β; h), Vss (liter/kg), renal clearance (mL/min/
kg), and 72-hour total renal excretion (Urine, 72 hours [% 
ID]) for a 0.1 mmol/kg dose were 1.78 ± 0.43, 0.21 ± 0.02, 
1.56 ± 0.18, and 98 ± 3.33, respectively. For a 0.4 mmol/kg 
dose, these values were 1.33 ± 0.21, 0.15 ± 0.02, 1.45 ± 0.22, 
and 96.6 ± 5.61, respectively. Plasma Gd-BT-DO3Al 
decreased bioexponentially, and the volume of distribution 
was within the extracellular fluid space. Elimination occurred 
primarily through the renal route. Biotransformation analysis 
of the urine and plasma samples revealed no metabolites 
from Gd-BT-DO3A. No significant changes were observed 
in serum chemistry/hematology or urine chemistry/
urinalysis. No clear dose-dependent adverse events were 
found between the low-dose and high-dose studies. The most 
common adverse events were smell sensation (12.5%) and 
taste sensation (15%). Essig et al40 compared 1 M Gd-BT-
DO3A with 0.5 M Gd-BOPTA in a Phase I, single-blinded, 
randomized intra-individual 1.5 T MRI brain perfusion 
imaging study. Doses of 0.1 and 0.2 mmol/kg were studied 
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in 12 male healthy volunteers. It was reported that both 
agents achieved similarly high-quality, diagnostically valid 
perfusion maps.
Tombach and Heindel41 and Huppertz and Rohrev42 sum-
marized studies for the clinical applications of 1 M Gd-BT-
DO3A. In 29 Phase I to Phase III studies (2523 subjects and 
2662 doses), Gd-BT-DO3A was distributed in the extracellular 
fluid with a plasma terminal t½ of 1.7–2 hours. Approximately 
98% of the dose was excreted unchanged in the urine within 
12 hours. The studies indicated that 1 M Gd-BT-DO3A had 
an excellent safety profile with doses ranging from 0.04 to 
1.5 mmol/kg. Overall, 8.5% of the patients reported related and 
unrelated adverse events. For contrast enhancement, analysis 
of efficacy data showed results comparable to results of other 
commercially available 0.5 M Gd-chelates in studies of the 
CNS (677 patients) and angiography (676 patients). In a study 
of the pharmacokinetics of 1 M Gd-BT-DO3A in 21 patients 
with chronic renal failure, Tombach et al43 reported that the 
extracellular distribution of Gd-BT-DO3A remained unchanged 
but the mean elimination t½ increased compared with that of 
healthy volunteers. Hahn et al44 studied the pharmacokinetics 
and safety of Gd-BT-DO3A in 130 pediatric patients aged 2–17 
years. The authors concluded that no adjustment for the adult 
dose of 0.1 mmol/kg is necessary for this age range and that 
Gd-BT-DO3A was safe and well tolerated in the study.
Anzalone et al45 and Kim et al46 compared 1 M 
Gd-BT-DO3A with 0.5 M Gd-DTPA in their clinical perfor-
mance of detecting brain metastases at 1.5 T MRI. At equal 
Gd dosage (0.1 mmol/kg), Anzalone et al45 reported that 
Gd-BT-DO3A appeared to produce improved lesion conspi-
cuity in ten out of the same group of 27 patients with at least 
one cerebral metastasis. Using double doses (0.2 mmol/kg) 
of both Gd-BT-DO3A and Gd-DTPA, Kim et al46 found 
Gd-BT-DO3A detected 25 additional lesions than that of 
Gd-DTPA (130 lesions) in the same 27 patients. The mean 
CNR was significantly higher (P = 0.00011) with Gd-BT-
DO3A (2.17 ± 0.19) than that of Gd-DTPA(1.9 ± 0.26).
In a multicenter, Phase II/III study of comparing 1 M 
Gd-BT-DO3A with 0.5 M Gd-HT-DO3A (0.2 mmol/kg), 
Katakami et al47 studied the efficacy and safety of two doses 
of Gd-BT-DO3A (0.1 and 0.2 mmol/kg) at 1.5 and 3 T MRI 
in 175 patients with brain metastases. The mean number of 
detected lesions per patient was 6.28, 6.92, and 6.87 for Gd-
BT-DO3A (0.1 mmol/kg), Gd-BT-DO3A (0.2 mmol/kg), and 
Gd-HT-DO3A, respectively. Overall clinical performance of 
Gd-BT-DO3A at both 0.1 and 0.2 mmol/kg was very similar 
to the 0.2 mmol/kg Gd-HT-DO3A. Another multicentric 
randomized intraindividual crossover comparison of 1 M 
Gd-BT-DO3A with 0.5 M Gd-DOTA in 136 brain tumor 
patients at 1.0 T MRI was reported by Anzalone et al.48 
At the dose of 0.1 mmol/kg Gd-BT-DO3A, there was a 
significantly higher qualitative and quantitative preference 
by independent blinded readers for Gd-BT-DO3A when 
compared to Gd-DOTA.
Voth et al52 reviewed and performed an integrated analysis 
of 34 clinical trials to assess the safety and tolerability of 
Gd-BT-DO3A. The review involved 4549 patients treated 
with gadobutrol for various clinical indications, including 
the CNS imaging (n = 2292). These trials were prospec-
tively planned and conducted between the years of 1993 
and 2009. A majority of the patients (n = 2434) received 
the generally recommended dose of 0.1 (±0.01) mmol/kg 
body weight. The rest of the patients received from less than 
0.09 to 0.51 mmol/kg body weight. Out of the total enrolled 
patients, 182 (4.0%) reported one or more adverse events.   
Out of all patients who had CNS imaging, 106 (4.6%) also 
reported one or more adverse events. In comparison, 74 
(4.0%) AEs were reported in 1822 patients treated with 
similar GBCAs (Gd-DTPA, n = 912; Gd-HP-DO3A, n = 555; 
Gd-DTPA-BMEA, n = 227; Gd-DTPA-BMA, n = 150). 
The most common AEs were headache, nausea, fever, and 
dysgeusia. Similar incidence rates were observed in pediat-
ric patients (5.8%), patients with severe or moderate renal 
impairment (2.5%), patients with severe or moderate hepatic 
impairment (4.2%), and patients with cardiovascular disor-
ders (2.8%). A review of post-marketing surveillance data 
from more than 5.7   million estimated gadobutrol adminis-
trations showed a total of 1175 (0.02%) AEs were reported. 
There were ten reported NSF for the entire reporting period 
up to February 2011. The review concluded that Gd-BT-
BO3A has an excellent safety profile and a positive benefit 
risk profile when used in clinically indicated CE-MRI.
A potential advantage of using 
gadobutrol in CE-MRI of the brain
Gd-BT-DO3A is a non-ionic, macrocyclic GBCA and was 
first approved in 1998 for clinical use in Switzerland. It is 
now approved for clinical use in 66 countries worldwide, 
including the EU, USA, Australia, Canada, China, South 
Africa, Mexico, New Zealand, Turkey, and some Eastern 
European and Asian countries.53 Gd-BT-DO3A is composed 
of a macrocyclic structure which has been shown to be more 
kinetically stable in vitro than GBCAs with linear, open-chain 
structures. This high stability may minimize the possibility 
of free toxic Gd+3 ions being released in vivo. Preclinical and 
clinical studies have shown that it has at least equivalent if 
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not better efficacy and safety profiles to other similar GBCAs. 
However, Gd-BT-DO3A has a distinguishing feature that it 
is the only clinical agent commercially available in a for-
mulation of 1.0 M concentration (Table 2). With this higher 
Gd concentration, Gd-BT-DO3A at 1.0 M has the highest 
in vitro T1 shortening effect per unit volume compared with 
other GBCAs at 0.5 M. Clinically, the double concentrated 
Gd-BT-DO3A allows for injection volume reduction without 
dose level changes and the compact bolus injected is better 
defined in vivo. This has been proven to be advantageous 
for some time-resolved MRI studies such as brain perfusion 
MRI or contrast-enhanced MRA.49,50 It is possible that even 
with the blood dilution and circulation, the double concen-
trated agent may still localize in the CNS at a relatively 
higher concentration than other comparable GBCAs. As a 
result, Gd-BT-DO3A may be able to achieve better contrast 
enhancement of brain lesion than other similar GBCAs at the 
same dose level. In light of potential NSF events associated 
with the use of all GBCAs,20,51 the probability of increasing 
their clinical efficacy without exposing the patient to a higher 
dose level may make this advantage more significant. Recent 
published multicenter clinical trials45–48 appeared to support 
this potential advantage of using Gd-BT-DO3A for CE-MRI 
of the brain. However, there is insufficient evidence to sug-
gest that the use of Gd-BT-DO3A will decrease the incidence 
of adverse events associated with the use of GBCAs.
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